PDCD1 and cancer: Our findings support a model that is suggestive of both T-cell activation as well as myeloid-cell signaling through FcγR engagement in an effective combination anti-cancer treatment of effector function enabled anti-TIGIT antibodies in combination with anti-PD-1.